Realm Therapeutics applies to trial novel allergic conjunctivitis therapy in the USA

2 August 2017

Realm Therapeutics (AIM: RLM) has submitted for approval to launch a Phase II trial for PR013, a candidate treatment for allergic conjunctivitis.

The UK-based biopharmaceutical firm, formerly known as PuriCore, aims to test the drug for patients aged 10 years and older in a multi-center, double-blind, randomized trial with approximately 90 subjects.

The planned trial will use a modified Conjunctival Allergen Challenge Model for assessment, the framework used by the majority of Food and Drug Administraton approved treatments in this area.

The company says that PR013, a high-concentration formulation of hypochlorous acid, has shown promise in in vitro studies at inhibiting both histaminergic and non-histaminergic itching associated with the disease. Antihistamines focus on the former only.

This advantage means that the company aims to address the unmet needs of approximately 30% of patients who do not respond to the current standard of care.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK